Endomag, the Cambridge-based developer of innovative solutions for cancer care, has appointed leading creative agency Mobas to handle its PR and marketing following the agency’s successful development of its new brand.
Mobas was initially appointed in early 2014 to investigate Endomag’s brand proposition and brand visual identity. The agency subsequently developed a new brand that reflects the business’ position today: growing from an early-stage technology start up to a company that is seeing clinical and commercial success across the world.
Since its formation in 2007, Endomag has been at the forefront of cancer care. Its unique technology removes the need for radioactive isotopes in the operating theatre by using iron oxide nanoparticles (Sienna+®) with a sensitive magnometer (Sentimag®) that detects the nanoparticles’ accumulation in lymph nodes. Endomag’s diagnostic products not only ensure that cancer staging is available to a far greater number of patients but also improve procedural convenience and put the surgeon in control.
Mobas will co-ordinate an ongoing global PR campaign from its Cambridge office, utilising its network of PR agencies to offer ‘on the ground’ support and knowledge.
Eric Mayes, CEO of Endomag, said: “With a growing portfolio of products and increasing demand across the globe, we’re in a very different place to when we formed in 2007. Every member of the Mobas team has impressed us with their expertise and understanding and we’re delighted with the new brand, messaging and the plans to roll out. We don’t have an in-house marketing function but, with Mobas, we don’t need one. We’re looking forward to a long and mutually beneficial relationship.”
Becky Lamont, Director of PR and Content at Mobas, said: “It’s a pleasure to work with a team who are as passionate about what they do as we are. We’ve been on a great journey with Endomag and are looking forward to continuing providing support across all areas of our expertise as the business continues to succeed and grow.”